{
    "name": "rifamycin",
    "comment": "Rx",
    "other_names": [
        "Aemcolo",
        "rifamycin SV MMX"
    ],
    "classes": [
        "Antibiotics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/aemcolo-rifamycin-sv-mmx-rifamycin-1000270",
    "pregnancy": {
        "common": [
            "There are no available data regarding use in pregnant women",
            "Systemic absorption in humans is negligible following PO administration; not expected that maternal use results in fetal exposure"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no available data regarding presence in human milk",
            "Systemic absorption in humans is negligible following PO administration; exposure to breastfed infants through breastmilk is expected to be negligible",
            "The development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to rifamycin or any of the other rifamycin-class antimicrobial agents"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not effective for diarrhea complicated by fever and/or bloody stool; discontinue use if diarrhea gets worse or persists >48 hr; consider alternative antibacterial therapy",
                "Consider Clostridium difficile-associated diarrhea (CDAD) in all patients who present with diarrhea following antibacterial drug use; CDAD can occur over 2 months after antibiotic discontinued",
                "Prescribing rifamycin without proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
                "Owing to minimal systemic rifamycin concentrations observed, clinically relevant drug interactions are not expected"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Constipation",
            "percent": "3.5"
        },
        {
            "name": "Headache",
            "percent": "3.3"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        }
    ]
}